Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Opioid Withdrawal: early-phase trial registry

4 of 10 indexed Opioid Withdrawal trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Opioid Withdrawal: 10 US clinical trials tracked, 4 recruiting.

Opioid Withdrawal is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Spark Biomedical, running 2 of these trials.

Enrollment posture brief

Registry condition opioid-withdrawal

OPEN 4 | RECR 40% | LATE 0 | EARLY 6 | RANK #1724 | SPON 2

Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Opioid Withdrawal (this)40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Opioid Withdrawal

Opioid Withdrawal lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Opioid Withdrawal on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Opioid Withdrawal is recruiting below its size-band peers.

    4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Opioid Withdrawal research.

    Spark Biomedical accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Opioid Withdrawal enrolment sits around 100 participants.

    Median target enrolment is 100 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.

  4. Opioid Withdrawal research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 1 240 participants

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

Medical University of South Carolina

NCT06442566

RECRUITING NA 60 participants

Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain

The University of Texas Medical Branch, Galveston

NCT05555485

RECRUITING Phase 2 60 participants

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

University of Maryland, Baltimore

NCT05027919

RECRUITING 20 participants

Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder

Spark Biomedical

NCT06487533

ACTIVE NOT RECRUITING Phase 1 160 participants

Sublingual Dexmedetomidine for Treating Opioid Withdrawal

New York State Psychiatric Institute

NCT05712707

ACTIVE NOT RECRUITING Phase 2 100 participants

Evaluating Buspirone to Treat Opioid Withdrawal

Johns Hopkins University

NCT05511909

COMPLETED Phase 1 225 participants

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

BioXcel Therapeutics

NCT04470050

COMPLETED NA 133 participants

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

Stanford University

NCT01549652

COMPLETED Phase 2 90 participants

Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

University of Pennsylvania

NCT04218240

COMPLETED NA 35 participants

Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

Spark Biomedical

NCT04075214

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3

Named interventions

Most-linked intervention names on Opioid Withdrawal records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Lofexidine Drug
2 trials
transcutaneous auricular neurostimulation (tAN) Device
1 trials
Naloxone 0.8 mg/70 kg Drug
1 trials
Naloxone 0.4 mg/70 kg Drug
1 trials
Lofexidine 0.18Mg Tab Drug
1 trials
Pregabalin 200 MG capsules Drug
1 trials
Lofexidine (Positive Control) Other
1 trials

US sites by state

Facility locations filed on Opioid Withdrawal trials. A trial with sites in several states counts in each.

New York 3 trials
Maryland 3 trials
Texas 2 trials
New Jersey 2 trials
South Carolina 1 trials
Pennsylvania 1 trials
Ohio 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Opioid Withdrawal page

10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Opioid Withdrawal trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Spark Biomedical sponsors the most Opioid Withdrawal trials on record, review their full trial history before evaluating a specific study. See Spark Biomedical's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Opioid Withdrawal condition card totals 10 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.